Literature DB >> 15750706

Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease.

Hans-Jürgen von Giesen1, Ortwin Adams, Hubertus Köller, Gabriele Arendt.   

Abstract

We compared CSF HIV viral load in 33 asymptomatic HIV seropositive patients, 11 patients with incipient minor motor deficits (MMD), 11 patients with sustained MMD, and 16 patients with HIV-associated dementia. Patients with incipient MMD showed significantly higher CSF viral load than asymptomatic patients. Demented patients also had higher CSF viral loads than asymptomatic patients. This phenomenon is independent of antiretroviral therapy. Thus, correlation of viral load with time suggests a multiphasic course of HIV-associated CNS disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750706     DOI: 10.1007/s00415-005-0749-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  31 in total

1.  Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children.

Authors:  R D Pratt; S Nichols; N McKinney; S Kwok; W M Dankner; S A Spector
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

Review 2.  Molecular analysis of cerebrospinal fluid: potential for the study of HIV-1 infection of the central nervous system.

Authors:  P Cinque; A Bestetti; P Morelli; S Presi
Journal:  J Neurovirol       Date:  2000-05       Impact factor: 2.643

3.  Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection.

Authors:  S Staprans; N Marlowe; D Glidden; T Novakovic-Agopian; R M Grant; M Heyes; F Aweeka; S Deeks; R W Price
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

4.  Motor analysis predicts progression in HIV-associated brain disease.

Authors:  G Arendt; H Hefter; F Hilperath; H J von Giesen; G Strohmeyer; H J Freund
Journal:  J Neurol Sci       Date:  1994-05       Impact factor: 3.181

5.  Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment.

Authors:  B J Brew; R B Bhalla; M Paul; J J Sidtis; J J Keilp; A E Sadler; H Gallardo; J C McArthur; M K Schwartz; R W Price
Journal:  AIDS       Date:  1992-05       Impact factor: 4.177

6.  Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death.

Authors:  N C Sacktor; H Bacellar; D R Hoover; T E Nance-Sproson; O A Selnes; E N Miller; G J Dal Pan; C Kleeberger; A Brown; A Saah; J C McArthur
Journal:  J Neurovirol       Date:  1996-12       Impact factor: 2.643

7.  Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.

Authors:  M Gisslén; L Hagberg; D Fuchs; G Norkrans; B Svennerholm
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-04-01

8.  Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia.

Authors:  S L Wesselingh; C Power; J D Glass; W R Tyor; J C McArthur; J M Farber; J W Griffin; D E Griffin
Journal:  Ann Neurol       Date:  1993-06       Impact factor: 10.422

9.  HIV-specific changes in the motor performance of HIV-positive intravenous drug abusers.

Authors:  H J von Giesen; H Hefter; H Roick; S Mauss; G Arendt
Journal:  J Neurol       Date:  1994-12       Impact factor: 4.849

10.  Comparison of human immunodeficiency virus biological phenotypes isolated from cerebrospinal fluid and peripheral blood.

Authors:  M F Peeters; R L Colebunders; K Van den Abbeele; P C Nys; J Goeman; P Colans; Y Geerts; G Van der Groen
Journal:  J Med Virol       Date:  1995-09       Impact factor: 2.327

View more
  7 in total

1.  In vivo characterization of macrophage-tropic simian immunodeficiency virus molecular clones in rhesus macaques.

Authors:  Sanjeev Gumber; Praveen Kumar Amancha; Po-Jen Yen; Francois Villinger; Dana Gabuzda; Siddappa N Byrareddy
Journal:  J Neurovirol       Date:  2018-03-28       Impact factor: 2.643

2.  Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.

Authors:  Patrick R Harrington; David W Haas; Kimberly Ritola; Ronald Swanstrom
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease.

Authors:  Sanneke Koekkoek; Laura Eggermont; Leo De Sonneville; Thidakat Jupimai; Saijai Wicharuk; Wichitea Apateerapong; Theshinee Chuenyam; Joep Lange; Ferdinand Wit; Chitsanu Pancharoen; Praphan Phanuphak; Jintanat Ananworanich
Journal:  J Neurol       Date:  2006-11-08       Impact factor: 4.849

Review 4.  Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS.

Authors:  Mark J Ferris; Charles F Mactutus; Rosemarie M Booze
Journal:  Neurosci Biobehav Rev       Date:  2008-03-18       Impact factor: 8.989

5.  Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease.

Authors:  Gabriele Arendt; Thorsten Nolting; Christian Frisch; Ingo-Wilhelm Husstedt; Nora Gregor; Eleni Koutsilieri; Mattias Maschke; Alexander Angerer; Mark Obermann; Eva Neuen-Jacob; Ortwin Adams; Sabine Loeffert; Peter Riederer; Volker ter Meulen; Sieghart Sopper
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

6.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

7.  Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia.

Authors:  Gretja Schnell; Serena Spudich; Patrick Harrington; Richard W Price; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2009-04-24       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.